| Popis: |
The nontargeted sampling of standard 12-core transrectal ultrasound (TRUS) biopsy has resulted in considerable undergrading of clinically significant prostate cancers. Magnetic resonance imaging (MRI)/transrectal ultrasound fusion-guided biopsy has emerged as an option for improved detection of prostate cancer. This novel technology, which combines high-resolution anatomic and functional prostate imaging via MRI with real-time TRUS biopsy probe guidance, allows for precise targeted biopsies of specified lesions. As initial studies have illustrated, this biopsy method has the potential to revolutionize the way prostate cancer is screened for, identified, and potentially treated. Herein, we provide a comprehensive review of the MRI/TRUS fusion biopsy technique, as well as a broad overview of the currently available fusion biopsy platforms and their clinical outcomes. |
